Premium
Endothelin‐1 and vein graft occlusion in patients undergoing bypass surgery
Author(s) -
Dashwood M. R.
Publication year - 2009
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.2009.02124.x
Subject(s) - medicine , endothelin receptor , vasoconstriction , cardiology , occlusion , vein , endothelium , constriction , vascular smooth muscle , endothelin 1 , artery , surgery , receptor , smooth muscle
The saphenous vein is the most commonly used graft for revascularization procedures in patients with coronary artery disease and critical limb ischaemia. However, the patency rate of this vessel is poor, with a high proportion of patients requiring further surgery. Early graft occlusion is caused by vasoconstriction or thrombus formation, with later stages of graft failure being due to neointimal formation or atherosclerosis. Apart from its potent constrictor action, endothelin‐1 is also a potent proliferative and proinflammatory peptide that is implicated in a number of vascular diseases. The surgical trauma caused during preparation of the saphenous vein as a bypass graft stimulates the release of a number of factors affecting vascular reactivity and structure, including endothelin‐1. Endothelin‐1 not only constricts animal and human isolated saphenous vein segments but also causes vascular smooth muscle proliferation and neointimal thickening in vitro , actions that are mediated via endothelin (A and B) receptors. Experimentally, the effects of subtype‐selective and dual receptor antagonists have been shown to inhibit endothelin‐1‐mediated constriction and cell proliferation of the saphenous vein. In this review, data supporting a role of endothelin‐1 in vein graft occlusion are presented, and the therapeutic potential of endothelin receptor antagonists in improving graft performance is discussed.